community download

Presentation: Marc La Force

information we require

please check before submitting



Unfortunately the document is not available at this current time, however if you leave your details we'll get it to you as soon as we can.

Please fill in all the information requested. It is very important you enter this information correctly so we can contact you with the document.

Privacy statement »

Manage your email preferences »

Remember my details Information

Information
Remember my details
We place a 'cookie' on your computer so next time you visit us you don't need to fill in all these details

Following the meningitis epidemic of 1996, African public health officials asked WHO to help them address the problem. Conjugate meningococcal vaccines were recommended following international meetings in 2000 and 2001. The Meningitis Vaccine Project was created in June 2001 to develop, test, license and implement the widespread use of conjugate meningococcal vaccines in Africa.

Meningitis Vaccine Project is working to eliminate epidemic meningitis as a public health problem in sub-Saharan Africa. This is a serious health issue in this region as over 90% of global meningococcal disease occurs in the African meningitis belt, where focal epidemics occur annually and major epidemics every 7-14 years. The success of this project is clearly evidenced in the results of the Burkina Faso campaign where 10.8 million people were immunized, details of which can be found in this presentation.

Early impact results after the introduction of a new Group A meningococcal conjugate vaccine in Africa:

• Impact data on vaccine mass-introduction to Sub-Saharan countries
• Project roll out information to eliminate large outbreaks
• Discover the unique cycle and possible future applications